Korea BMS Pharma (CEO: Park Hye-sun) presented their research of genotype 1b hepatitis C at “The Liver Week 2017,” an international conference held at the Grand Hyatt, Incheon, from June 22-24.
The real-life data for Koreans in the multicenter-based treatment regimen is based on the results of a total of 591 genotype 1b hepatitis C patients treated at eight CMC hospitals.
The results showed SVR 12 (sustained viral response rate for 12 weeks) of 95.2 percent (n = 316/332) in the actual treatment environment for Korean patients, similar to that of clinical trials. In particular, it showed SVR12 of 95.8 percent (n = 294/307) among patients without NS5A resistance mutation. Also, the combination therapy with concurrent hepatitis C showed a consistent treatment effect, including 93.8 percent among patients with cirrhosis and 95.7 percent among patients without cirrhosis.
"The results of this real-life data analysis showed that the combination therapy with Daklinza-Sunvepra showed excellent efficacy and safety consistent with clinical studies,” said Professor Jang Jung-won at the Department of Internal Medicine, Seoul St. Mary's Hospital. "Proven effectiveness and security in non-clinical, actual prescription experience is a fundamental basis for physicians and patients choosing therapeutic agents."
Korea-BMS Pharma appeared encouraged. "In Korea, the first DAA drug, Daklinza - Sunvepra, has been recognized for its efficacy and safety through over 10,000 treatments since its launch,” said Lee Seung-hoon, managing director of BMS Pharmaceutical Division, Korea. "Based on this, we will increase the trust of patients and medical staff and make efforts to contribute to the cure of hepatitis C."
About 600 liver diseases experts attended the symposium, a place to share the latest knowledge of experts in the field of hepatitis B and C treatment. Professor Kim Yoon-joon of Seoul National University Hospital made a presentation on "Lessons Learned from Experiencing Hepatitis B Real Life Therapy.”
<© Korea Biomedical Review, All rights reserved.>